Research and Clinical Trials

Research and Clinical Trials

Find research and clinical trial information for Pediatric Endocrinology at Penn State Children’s Hospital. 

Call our office for more information



Penn State Children’s Hospital stays on the leading edge of treatment for diabetes and hormone disorders in children by taking part in research and clinical trials.

Type 1 Diabetes Research

The TrialNet study is a natural history study of the development of Type 1 diabetes. The overall goal of this study is to perform baseline and repeat assessments over time of the metabolic and immunologic status of individuals at risk for Type 1 diabetes (T1D) to:

  • Characterize their risk for developing T1D and identify subjects eligible for prevention trials.
  • Describe the pathogenic evolution of T1D.
  • Increase the understanding of the pathogenic factors involved in the development of T1D.

The study subjects include:

  • First-degree relatives (parent, child, brother, sister) of T1D probands (the first individual in a family with Type 1 diabetes), ages 1 – 45 years.
  • Second and third degree relatives (nieces, nephews, aunts, uncles, grandchildren, cousins, half-siblings) of T1D probands, ages 1 – 20 years.

Status: Institutional Review Board (IRB) approved.

For more information, please call 717-531-4751.

Type 2 Diabetes Clinical Trial

This trial studies the effectiveness and safety of several diabetes medications in children age 10 to 16 years with Type 2 diabetes, specifically:

  • Liraglutide in combination with metformin versus Metformin monotherapy on glycaemic control 

This is a 26-week double-blind, randomized, parallel group, placebo controlled multi-centre trial followed by a 26-week open-label extension.

During the trial, children with Type 2 diabetes are randomly assigned into metformin therapy or metformin plus liraglutide. Liraglutide is a medicine belonging to glucagon like peptide-1 (GLP-1), which is a potent glucose lowering agent used for Type 2 diabetes treatment. Liraglutide is given via subcutaneous injection, once a day.

Status: Actively enrolling

For more information, please call 717-531-4751.

Contact us

Scheduling: 717-531-4751
Fax: 717-531-6139

Academic Office: 717-531-1481